Ian Myers, MD
Family Medicine · Newark, DENPI 1194783019
Payments from drug & device makers
Across 758 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Johnson & Johnson$2K
- GSK$2K
- Novo Nordisk$2K
- AbbVie$1K
- Amgen$1K
- plus $5K from 32 others
What the payments were for
- Food & beverage$16,824100%
- Education$440%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 109 | $3,063 |
| Johnson & Johnson | 35 | $2,262 |
| GSK | 107 | $2,130 |
| Novo Nordisk | 74 | $1,668 |
| AbbVie(2 entities) | 73 | $1,298 |
| Amgen(2 entities) | 73 | $1,243 |
| Astellas Pharma US Inc | 48 | $938 |
| Pfizer | 56 | $872 |
| Lilly USA, LLC | 45 | $638 |
| Abbott | 25 | $534 |
| Bayer | 23 | $530 |
| Merck | 24 | $338 |
| Idorsia Pharmaceuticals US Inc | 11 | $256 |
| Teva Pharmaceuticals USA, Inc. | 3 | $151 |
| Exact Sciences | 9 | $146 |
| Eisai Inc. | 8 | $118 |
| Phathom Pharmaceuticals, Inc. | 2 | $81 |
| Novartis | 5 | $76 |
| Amarin Pharma, Inc. | 4 | $62 |
| Biohaven Pharmaceuticals, Inc. | 1 | $56 |
| Kowa Pharmaceuticals America, Inc. | 4 | $48 |
| Dexcom, Inc. | 1 | $38 |
| Scilex Pharmaceuticals Inc. | 2 | $36 |
| Tactile Systems Technology Inc | 1 | $30 |
| Shire North American Group Inc | 2 | $29 |
| Alkermes, Inc. | 1 | $28 |
| Shield Therapeutics Inc | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Medtronic | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Seqirus USA Inc | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| UCB, Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,868 in reported general payments places this provider in the 95th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 62 | $89,166 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 89 | $84,420 |
| JanuviaSitagliptin Phosphate | 22 | $33,217 |
| XareltoRivaroxaban | 20 | $30,761 |
| ProliaDenosumab | 16 | $26,834 |
| OzempicSemaglutide | 17 | $24,920 |
| TradjentaLinagliptin | 32 | $21,607 |
| TrulicityDulaglutide | 21 | $20,845 |
| MounjaroTirzepatide | 16 | $16,614 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 47 | $14,212 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 51 | $11,168 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $11,052 |
| Atorvastatin Calcium | 398 | $4,702 |
| SynthroidLevothyroxine Sodium | 55 | $3,732 |
| Adacel TdapDiph,pertuss(Acell),tet Vac/Pf | 30 | $2,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arexvy, Shingrix, Anoro Ellipta | $2,130 | $120,852201 claims |
| AstraZenecaFarxiga | $3,063 | $89,16662 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $638 | $37,45937 claims |
| MerckJanuvia | $338 | $33,21722 claims |
| Johnson & JohnsonXarelto | $2,262 | $30,76120 claims |
| AmgenProlia | $1,243 | $26,83416 claims |
| Novo NordiskOzempic | $1,668 | $24,92017 claims |
| Boehringer IngelheimTradjenta | $15 | $21,60732 claims |
| AbbVieSynthroid | $1,298 | $3,73255 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 352 family medicine providers in Delaware.
Other family medicine in Newark
- Michelle PapaNewark$23K
- Robert WinterNewark$12K
- Judy LimNewark$12K
- Huy leNewark$10K
- Arlen StoneNewark$10K
- Imelyn LaheyNewark$8K
- Angela Davis BrownNewark$8K
- Robert CallahanNewark$7K
- George NameyNewark$6K
- William FunkNewark$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.